Metformin in Perimenopause: Insulin Resistance, PCOS History and Weight
There is a particular woman for whom metformin is more than a diabetes drug she has never needed. She is in her mid-to-late forties; her weight has moved to her middle over three or four years despite no change in habits; her fasting insulin has crept up; and somewhere in her history — often decades ago, often half-forgotten — is a PCOS diagnosis, irregular periods, or a pregnancy with gestational diabetes.
This page is about her, and about where metformin sits for her against hormone therapy and the GLP-1 medications. The main metformin page and the prediabetes page cover the drug generally.
What the transition does to insulin
Estrogen helps muscle and liver respond to insulin. As it declines across perimenopause, insulin sensitivity falls with it — independently of age, independently of weight — and the body compensates by making more insulin. That is the mechanism behind the weight redistribution of the transition: visceral fat is where surplus energy goes when insulin is high and estrogen is low, and visceral fat in turn worsens insulin resistance. It is a loop, and it tightens through the late forties and early fifties.
A fasting insulin rises years before glucose does; a HOMA-IR makes the trend visible. That is why we draw both, and why a woman in the transition with a "normal" glucose can be well along the path.
Why a PCOS history changes the picture
Polycystic ovary syndrome is, at its core, an insulin-resistance condition with reproductive consequences. A woman who had it at 25 does not stop having it at 45; the irregular periods and fertility issues recede as the ovaries wind down, but the metabolic side remains and now meets the transition's own insulin resistance. Women with PCOS have roughly twice the lifetime risk of type 2 diabetes and reach it earlier. Gestational diabetes tells a similar story: it is the insulin resistance of pregnancy unmasking a predisposition, and it predicts type 2 diabetes with a sevenfold increase in risk over the following decade.
Metformin has decades of use in PCOS — for cycle regulation, for insulin resistance, for the metabolic risk — and in the Diabetes Prevention Program the subgroup with a history of gestational diabetes was one where metformin matched lifestyle intervention, reducing progression to diabetes by around half. For a perimenopausal woman with either history, it is a drug with a specific claim on her situation, not a generic one.
Where it sits against the alternatives
Hormone therapy addresses the estrogen loss that drives the transition's insulin resistance, and estradiol in the timing window modestly improves insulin sensitivity and blunts the shift to abdominal fat — see does estradiol cause weight gain. It does not treat established insulin resistance on its own, and the two are often used together: estrogen for the hormonal driver, metformin for the metabolic one.
GLP-1 medications produce far larger weight loss and, in tirzepatide's case, a much larger reduction in diabetes progression — the tirzepatide prediabetes page has the numbers. For a woman whose weight is the main problem and whose insulin resistance is advanced, they are the stronger tool. Metformin is the lighter one: cheaper, oral, with a longer safety record, appropriate when the numbers are early or the preference is for the least drug that does something. Some women use both, on clinical judgement.
Metformin alone is the reasonable first choice for the woman with a PCOS or gestational-diabetes history, a rising fasting insulin, modest weight to lose, and a wish to intervene early and lightly — and it is often the right choice to make before the transition's insulin resistance compounds what she already has.
What we measure
Fasting glucose, fasting insulin and A1c at baseline and on a schedule; lipids with ApoB, because insulin resistance moves them; liver enzymes, because fatty liver travels with this picture; and the hormone panel that places her in the transition. B12 on metformin, as always. And the history taken properly — PCOS, gestational diabetes, a family history of type 2 — because it changes the answer and it is the part most often left out of a weight consultation.
Frequently asked questions
Modestly, where insulin resistance is driving it. It is not a weight-loss drug; it treats the insulin resistance that makes the transition's weight harder to shift. GLP-1 medications produce far more weight loss.
Yes. The metabolic side of PCOS persists after the reproductive symptoms fade, and it compounds the insulin resistance of the transition. It roughly doubles lifetime diabetes risk.
It is one of the groups where metformin performed best in the Diabetes Prevention Program. Whether it is right for you depends on your current numbers; the history moves you up the list for measuring them.
Yes, commonly. They address different drivers — estrogen loss and insulin resistance — and there is no interaction between them.
Metformin where the numbers are early and the preference is for a light intervention; a GLP-1 where weight is the main problem or the metabolic picture is advanced. Sometimes both.
Not directly. In PCOS it can improve cycle regularity by improving insulin sensitivity, but it is not a hormone and does not replace one.
Where this fits in your plan
A baseline panel with fasting insulin and the hormone markers, plus a history that asks about PCOS and pregnancy, tells us where you are. The Metformin page covers the drug; the menopause page covers the transition.
We measure first. Then we act.
References
- Aroda VR et al. The effect of lifestyle intervention and metformin on preventing or delaying diabetes among women with and without gestational diabetes: the Diabetes Prevention Program Outcomes Study 10-year follow-up. JCEM 2015;100:1646–1653.
- Teede HJ et al. Recommendations from the 2023 international evidence-based guideline for the assessment and management of polycystic ovary syndrome. Human Reproduction 2023;38:1655–1679.
- Vounzoulaki E et al. Progression to type 2 diabetes in women with a known history of gestational diabetes: systematic review and meta-analysis. BMJ 2020;369:m1361.
- Lovejoy JC et al. Increased visceral fat and decreased energy expenditure during the menopausal transition. International Journal of Obesity 2008;32:949–958.
- Moran LJ et al. Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary syndrome: a systematic review and meta-analysis. Human Reproduction Update 2010;16:347–363.
- Back toMetformin
- Metformin for prediabetesTwenty years of evidence say metformin cuts progression to diabetes by about a third — and say exactly who benefits most. Where it fits against lifestyle and a GLP-1.Read
- Does estradiol cause weight gain?The most common reason women refuse hormone therapy is a fear the trials do not support. What estradiol does and does not do to weight, fat distribution and fluid.Read
- Why weight changes in menopauseMenopause changes where fat is stored more than how much. Why the redistribution matters more than the scale, and what actually influences it.Read
How we write and review our content
ACT 2 Health provides clinician-led care. Treatments are available only to eligible patients following clinical evaluation and within applicable regulations. This content is educational and is not medical advice. Individual results vary.
Diagnostic testing does not diagnose or rule out disease on its own and is interpreted by a licensed provider alongside your history and examination.
All medical decisions are made solely by licensed healthcare professionals. Medications are prescribed only when medically necessary. GLP-1 medications are not suitable for everyone. Results may vary.
Care is delivered via telemedicine by healthcare professionals licensed in the state where the patient is located. Services are available only in states where our providers are licensed.